Alvotech (NASDAQ: ALVO), a global biotechnology company developing biosimilar medicines, has reported strong financial results for the first quarter of 2025, driven by substantial growth in product revenue.
A biosimilar is a biological medicine that is highly similar to and has no clinically meaningful differences from an existing approved biological or reference product.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com